Improving Postapproval Drug Safety Surveillance: Getting Better Information Sooner

Literature Cited

1. Gu Q, Dillon CF, Burt VL. 1.  2010. Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008. NCHS Data Brief No. 42, US Dep. Health Hum. Serv., Cent. Dis. Control Prev., Natl. Cent. Health Stat., Hyattsville, MD. http://www.cdc.gov/nchs/data/databriefs/db42.htm
2. Pirmohamed M, James S, Meakin S, Green C, Scott AK. 2.  et al. 2004. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15–19 [Google Scholar]
3. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. 3.  2003. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann. Intern. Med. 138:161–67 [Google Scholar]
4. Ruiter R, Visser LE, Rodenburg EM, Trifiro G, Ziere G, Stricker BH. 4.  2012. Adverse drug reaction–related hospitalizations in persons aged 55 years and over: a population-based study in the Netherlands. Drugs Aging 29:225–32 [Google Scholar]
5. Otway HJ, von Winterfeldt D. 5.  1982. Beyond acceptable risk: on the social acceptability of technologies. Policy Sci. 14:247–56 [Google Scholar]
6. Lasser KE, Himmelstein DU, Woolhandler SJ, McCormick D, Bor DH. 6.  2002. Do minorities in the United States receive fewer mental health services than whites?. Int. J. Health Serv. 32:567–78 [Google Scholar]
7. Lester J, Neyarapally GA, Lipowski E, Graham CF, Hall M, Dal Pan G. 7.  2013. Evaluation of FDA safety-related drug label changes in 2010. Pharmacoepidemiol. Drug Saf. 22:302–5 [Google Scholar]
8. Moore TJ. 8.  1995. Deadly Medicine: Why Tens of Thousands of Heart Patients Died in America's Worst Drug Disaster New York: Simon & Schuster
9. Graham DJ, Campen D, Hui R, Spence M, Cheetham C. 9.  et al. 2005. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475–81 [Google Scholar]
10. Taussig HB. 10.  1962. Thalidomide and phocomelia. Pediatrics 30:654–59 [Google Scholar]
11. Brewer T, Colditz GA. 11.  1999. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 281:824–29 [Google Scholar]
12. 12. Advis. Comm. Surg. Gen. Public Health Serv 1964. Smoking and health. Public Health Serv. Publ. No. 1103, US Dep. Health, Educ., Welf., Washington, DC. http://profiles.nlm.nih.gov/ps/access/NNBBMQ.pdf
13. 13. Collab. Group Horm. Factors Breast Cancer. 1996. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713–27 [Google Scholar]
14. MacMahon B, Yen S, Trichopoulos D, Warren K, Nardi G. 14.  1981. Coffee and cancer of the pancreas. N. Engl. J. Med. 304:630–33 [Google Scholar]
15. Wynder EL, Hall NE, Polansky M. 15.  1983. Epidemiology of coffee and pancreatic cancer. Cancer Res. 43:3900–6 [Google Scholar]
16. Hammerness PG, Surman CB, Chilton A. 16.  2011. Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications. Curr. Psychiatry Rep. 13:357–63 [Google Scholar]
17. Nissen SE. 17.  2006. ADHD drugs and cardiovascular risk. N. Engl. J. Med. 354:1445–48 [Google Scholar]
18. Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C. 18.  et al. 2011. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 127:1102–10 [Google Scholar]
19. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG. 19.  et al. 2011. ADHD drugs and serious cardiovascular events in children and young adults. N. Engl. J. Med. 365:1896–904 [Google Scholar]
20. Olfson M, Huang C, Gerhard T, Winterstein AG, Crystal S. 20.  et al. 2012. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 51:147–56 [Google Scholar]
21. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC. 21.  et al. 2010. Warfarin pharmacogenetics: A single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115:3827–34 [Google Scholar]
22. Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S. 22.  2010. Fibrate/statin initiation in warfarin users and gastrointestinal bleeding risk. Am. J. Med. 123:151–57 [Google Scholar]
23. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL. 23.  et al. 2013. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369:242283–93 [Google Scholar]
24. 24. Peripher. Cent. Nerv. Syst. Drugs Advis. Comm., Psychopharmacol. Drugs Advis. Comm 2008. Summary minutes of the joint meeting of the Peripheral and Central Nervous System Advisory Committee and the Psychopharmacologic Drugs Advisory Committee Food Drug Adm. Cent. Drug Eval. Res., Beltsville, MD
25. Lindquist M, Edwards IR. 25.  1997. Risks of non-sedating antihistamines. Lancet 349:1322 [Google Scholar]
26. de Abajo FJ, Rodriguez LA. 26.  1999. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br. J. Clin. Pharmacol. 47:307–13 [Google Scholar]
27. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. 27.  2001. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am. J. Gastroenterol. 96:1698–703 [Google Scholar]
28. Hennessy S, Leonard CE, Newcomb C, Kimmel SE, Bilker WB. 28.  2008. Cisapride and ventricular arrhythmia. Br. J. Clin. Pharmacol. 66:375–85 [Google Scholar]
29. Staffa JA, Chang J, Green L. 29.  2002. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 346:539–40 [Google Scholar]
30. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD. 30.  et al. 2004. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292:2585–90 [Google Scholar]
31. McGuinness ME, Talbert RL. 31.  1993. Phenformin-induced lactic acidosis: a forgotten adverse drug reaction. Ann. Pharmacother. 27:1183–87 [Google Scholar]
32. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. 32.  2010. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2010.4CD002967
33. Ekstrom N, Schioler L, Svensson AM, Eeg-Olofsson K, Miao Jonasson J. 33.  et al. 2012. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2:4e001076 doi: 10.1136/bmjopen-2012-001076 [Google Scholar]
34. Brown JS, Holmes JH, Shah K, Hall K, Lazarus R, Platt R. 34.  2010. Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med. Care 48:S45–51 [Google Scholar]
35. Reisinger SJ, Ryan PB, O'Hara DJ, Powell GE, Painter JL. 35.  et al. 2010. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. J. Am. Med. Inform. Assoc. 17:652–62 [Google Scholar]
36. Maro JC, Platt R, Holmes JH, Strom BL, Hennessy S. 36.  et al. 2009. Design of a national distributed health data network. Ann. Intern. Med. 151:341–44 [Google Scholar]
37. Toh S, Reichman ME, Houstoun M, Southworth MR, Ding X. 37.  et al. 2012. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch. Intern. Med. 172:1582–89 [Google Scholar]
38. Psaty BM, Larson EB. 38.  2013. Investments in infrastructure for diverse research resources and the health of the public. JAMA 309:1895–96 [Google Scholar]
39. Toh S, Reichman ME, Houstoun M, Ding X, Fireman BH. 39.  et al. 2013. Multivariable confounding adjustment in distributed data networks without sharing of patient-level data. Pharmacoepidemiol. Drug Saf. 22:1171–77 [Google Scholar]
40. Li X, Hui S, Ryan P, Rosenman M, Overhage M. 40.  2013. Statistical visualization for assessing performance of methods for safety surveillance using electronic databases. Pharmacoepidemiol. Drug Saf. 22:503–9 [Google Scholar]
41. Avery TR, Kulldorff M, Vilk Y, Li L, Cheetham TC. 41.  et al. 2013. Near real-time adverse drug reaction surveillance within population-based health networks: methodology considerations for data accrual. Pharmacoepidemiol. Drug Saf. 22:488–95 [Google Scholar]
42. Southworth MR, Reichman ME, Unger EF. 42.  2013. Dabigatran and postmarketing reports of bleeding. N. Engl. J. Med. 368:1272–74 [Google Scholar]
43. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J. 43.  et al. 2009. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361:1139–51 [Google Scholar]
44. Kulldorff M, Dashevsky I, Avery TR, Chan AK, Davis RL. 44.  et al. 2013. Drug safety data mining with a tree-based scan statistic. Pharmacoepidemiol. Drug Saf. 22:517–23 [Google Scholar]
45. Moses C, Celi LA, Marshall J. 45.  2013. Pharmacovigilance: an active surveillance system to proactively identify risks for adverse events. Popul. Health Manag. 16:147–49 [Google Scholar]
46. Reps J, Garibaldi JM, Aickelin U, Soria D, Gibson JE, Hubbard RB. 46.  2012. Comparing data-mining algorithms developed for longitudinal observational databases. Presented at 12th Annu. Workshop Comput. Intell., Edinb., UK. http://arxiv.org/abs/1307.1584
47. Wang Z, Kim S, Quinney SK, Guo Y, Hall SD. 47.  et al. 2009. Literature mining on pharmacokinetics numerical data: a feasibility study. J. Biomed. Inform. 42:726–35 [Google Scholar]
48. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. 48.  2010. A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 6:343 [Google Scholar]
49. Hadzi-Puric J, Grmusa J. 49.  2012. Automatic drug adverse reaction discovery from parenting websites using disproportionality methods. Presented at 2012 IEEE/ACM Int. Conf. Adv. Soc. Netw. Anal. Min. (ASONAM), Istanb., Turk.
50. Mao JJ, Chung A, Benton A, Hill S, Ungar L. 50.  et al. 2013. Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol. Drug Saf. 22:256–62 [Google Scholar]
51. Arrell DK, Terzic A. 51.  2013. Interpreting networks in systems biology. Clin. Pharmacol. Ther. 93:389–92 [Google Scholar]
52. Berger SI, Iyengar R. 52.  2009. Network analyses in systems pharmacology. Bioinformatics 25:2466–72 [Google Scholar]
53. 53. Inst. Med. (IOM) 2012. Ethical and Scientific Issues in Studying the Safety of Approved Drugs Washington, DC: Natl. Acad. Press http://www.iom.edu/Reports/2012/Ethical-and-Scientific-Issues-in-Studying-the-Safety-of-Approved-Drugs.aspx
54. Dunson DB. 54.  2001. Commentary: practical advantages of Bayesian analysis of epidemiologic data. Am. J. Epidemiol. 153:1222–26 [Google Scholar]
55. Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Grosbein HA, Feldman BM. 55.  2010. A valid and reliable belief elicitation method for Bayesian priors. J. Clin. Epidemiol. 63:370–83 [Google Scholar]
56. Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Feldman BM. 56.  2010. Methods to elicit beliefs for Bayesian priors: a systematic review. J. Clin. Epidemiol. 63:355–69 [Google Scholar]
57. Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Hawker GA, Feldman BM. 57.  2011. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH: belief elicitation for Bayesian priors. J. Rheumatol. 38:462–69 [Google Scholar]
58. Suissa S, Henry D, Caetano P, Dormuth CR, Ernst P. 58.  et al. 2012. CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med. 6:e134–40 [Google Scholar]
59. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF. 59.  et al. 2013. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 346:f880 [Google Scholar]
60. Coloma PM, Schuemie MJ, Trifiro G, Gini R, Herings R. 60.  et al. 2011. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR project. Pharmacoepidemiol. Drug Saf. 20:1–11 [Google Scholar]
61. Avillach P, Coloma PM, Gini R, Schuemie M, Mougin F. 61.  et al. 2013. Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. J. Am. Med. Inform. Assoc. 20:184–92 [Google Scholar]
62. 62. Platt R, Carnahan RM 2012. The U.S. Food and Drug Administration's Mini-Sentinel Program. Pharmacoepidemiol Drug Saf. 21:Suppl. S11–303 [Google Scholar]
63. 63. Mini-Sentinel Coord. Cent. 2013. Mini-Sentinel distributed database “at a glance.” Updated Sept. 22, 2013. http://mini-sentinel.org/about_us/MSDD_At-a-Glance.aspx
64. Robb MA, Racoosin JA, Worrall C, Chapman S, Coster T, Cunningham FE. 64.  2012. Active surveillance of postmarket medical product safety in the Federal Partners' Collaboration. Med. Care 50:948–53 [Google Scholar]
65. Zornberg GL, Hsu L, Dong D, Wernecke M, Kim C. 65.  et al. 2011. Dronedarone or amiodarone and risk of heart failure (HF): a Federal Partners' Collaboration (FPC). Pharmacoepidemiol. Drug Saf. 20:Suppl. 1S26 (Abstr.) [Google Scholar]
66. DeStefano F, Vaccine. 66.  Saf. Datalink Res. Group 2001. The Vaccine Safety Datalink project. Pharmacoepidemiol. Drug Saf. 10:403–6 [Google Scholar]
67. Davis RL. 67.  2013. Vaccine safety surveillance systems: critical elements and lessons learned in the development of the US Vaccine Safety Datalink's rapid cycle analysis capabilities. Pharmaceutics 5:168–78 [Google Scholar]
68. Davis RL, Kramarz P, Bohlke K, Benson P, Thompson RS. 68.  et al. 2001. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease. JAMA Pediatr. 155:354–59 [Google Scholar]